Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 3, 2011 Frank Vinluan	GSK Settles With Uncle Sam for $3B GSK said the settlement will reduce financial uncertainty for the company and is in the best interest of shareholders.
Chemistry World September 17, 2013 Phillip Broadwith	GSK criticized for trial data secrecy An Italian research institute has withdrawn from a public -- private partnership after quarrelling with GlaxoSmithKline about access to data from an antibiotic clinical trial being run by the institute.
BusinessWeek January 29, 2007 Kerry Capell	GlaxoSmithKline: Getting AIDS Drugs To More Sick People GlaxoSmithKline sells 90% of its vaccines, in volume terms, at not-for-profit prices to customers in the developing world.
Chemistry World December 5, 2014 Andy Extance	GSK cuts US jobs in push for savings 350 of the chemists, engineers and other roles will be lost by April 2015, another 450 by July, and the remainder eliminated by the end of the year.
Pharmaceutical Executive September 1, 2008 Sarah Houlton	Doing More With Less In order to take a big step forward, GlaxoSmithKline looks to employ smaller licensing deals and business units.
Chemistry World September 25, 2014 Hepeng Jia	GSK fined 300 million for China corruption After investigation by Chinese police, the British pharmaceutical giant GlaxoSmithKline was fined a record Yuan3 billion ( 300 million pounds) for bribing Chinese doctors and hospital officials.
Chemistry World February 7, 2013 Maria Burke	GSK commits to AllTrials data disclosure GlaxoSmithKline has become the first pharmaceutical company to sign up to a high-profile campaign to make detailed data on all clinical trials available to the public.
The Motley Fool July 26, 2011 Cliff D'Arcy	GSK Showers Shareholders With Cash GlaxoSmithKline, the U.K.'s largest pharmaceutical company, has released its second-quarter results. Thanks to rising earnings and dividends, its shares remain attractively priced, particularly to income-seeking investors.
Chemistry World October 1, 2008 Victoria Gill	GSK to Cut 850 R&D Jobs GlaxoSmithKline has announced that up to 850 R&D jobs will be cut as it implements its new business strategy.
Chemistry World February 4, 2010 Matt Wilkinson	More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets.
The Motley Fool January 19, 2011 Cliff D'Arcy	Glaxo Stung by Legal Bill GSK shareholders are hit by costly legal settlements.
Chemistry World April 25, 2014 Andy Extance	$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees.
Chemistry World October 2011 Bibiana Campos Seijo	Editorial: Odd Couple McLaren's expertise in building Formula One cars is to be put to use in the manufacture of antibiotics, vaccines and Lucozade in an unlikely alliance between the motor racing team and GlaxoSmithKline.
Pharmaceutical Executive July 1, 2005 Sarah Houlton	Global Report: Still Waiting Pharma industry and traders both want a decision on parallel trade in Europe--but not the same one.
Pharmaceutical Executive October 1, 2011	The Legacy of High Expectations Andrew Witty, Chairman & CEO, GlaxoSmithKline, believes the pharmaceutical industry will continue to make a significant contribution to society if it continues to improve the way it goes about its work.
The Motley Fool June 14, 2007 Brian Lawler	Dueling Fools: GlaxoSmithKline Bull Rebuttal Investors who think this pharma's market cap is too large would be missing out on the chance to own one of the best-run companies in the most exciting industry.
The Motley Fool June 14, 2007 Brian Lawler	Dueling Fools: GlaxoSmithKline Bull Shares of the pharmaceutical may be temporarily down, but it's not out.
AFP eWire September 25, 2012 Mary Deacon	Developing Effective Nonprofit -- Corporate Relationships The world is facing challenging economic conditions. Charities are proliferating to meet the needs created by less funding from governments and traditional philanthropic sources and are faced with more competition for seemingly fewer resources.
Chemistry World October 17, 2012 Maria Burke	GSK pledge on trials transparency GlaxoSmithKline has announced a series of initiatives to make clinical trial data publically available that could set a precedent in an industry not known for its transparency.
The Motley Fool September 15, 2011 Frank Vinluan	GSK's New Drug Marketing Model: Pharma Reps As Educators, Not Sellers The conversation between sales reps and doctors today is vastly different compared to one year ago.
The Motley Fool April 15, 2011 Frank Vinluan	GSK to Shed Weight Loss Drug alli and 18 Others GSK wants to focus on fast-growing "priority brands."
Chemistry World August 6, 2014 Hepeng Jia	GSK's China troubles continue The company faces official prosecution over accusations of bribery and corruption, litigation from fired employees and an upcoming trial of private investigators employed to look into a blackmail attempt.
Pharmaceutical Executive February 1, 2009 Joanna Breitstein	Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most.
Chemistry World May 14, 2014 Phillip Broadwith	Chinese police hand GSK bribery case to prosecutors The Chinese state news agency Xinhua has released details of the police investigation, claiming that 46 suspects are involved including Mark Reilly, former manager of GSK China.
Pharmaceutical Executive August 1, 2012 Ben Comer	Compliance Kulture: The Facts Behind GSK's CIA Big Pharma talks a lot about changing its business model to one that prioritizes quality and value over quantity and waste. How do you judge a sales rep's performance if not on how much she sells?
The Motley Fool October 26, 2006 Brian Lawler	Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth.
Chemistry World November 28, 2012 Andrew Turley	GSK expands in India and Nigeria GlaxoSmithKline is to spend 650 million pounds dramatically increasing its ownership of Indian and Nigerian subsidiaries.
The Motley Fool April 5, 2011 Frank Vinluan	GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep.
Chemistry World July 29, 2013 Hepeng Jia	China corruption investigation broadens Investigations of corrupt practices at GlaxoSmithKline in China are continuing. But analysts claim that the scandal is an attempt to remodel the Chinese drugs market, rather than a deliberate attack on international companies.
Chemistry World September 24, 2010 Andrew Turley	End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use.
Pharmaceutical Executive August 1, 2012 Stan Bernard	Creallaborations: Pharma Starts Thinking Outside the Pill Box Creative non-pharmaceutical partnerships can offer innovators unique capabilities against the competition in a new era where challenges to market leadership are coming from every direction.
Pharmaceutical Executive October 1, 2006 Sarah Houlton	Global Report: Please Come Back Health authorities in Europe are working hard to reestablish their countries as preferred locations for pharma's R&D facilities. Fortunately, they've got a blueprint: China.
Chemistry World March 22, 2012 Andrew Turley	GSK to build 350 million factory in UK GlaxoSmithKline has announced plans to build its first new UK production plant for almost 40 years in Ulverston, Cumbria.
The Motley Fool September 6, 2007 Brian Lawler	Foolish Fantasy Football: GlaxoSmithKline on Defense In real life, defense wins championships. This stock analyst includes GlaxoSmithKline on his fantasy football investment team, to shield from a punishing sack by the market.
BusinessWeek April 26, 2004 Kerry Capell	Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money.
Chemistry World April 20, 2009 Phil Taylor	GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'.
Chemistry World December 22, 2010 Sarah Houlton	Fines, Flu and an Uncertain Future It was another tough year for the pharma industry, with downsizing, pricing concerns and the impending expiration of patents on many products. But some of the biggest headlines were caused by eye-watering fines dished out in the US.
AskMen.com Samuel Hui	Fine Living: Smart Philanthropy To help develop a sound and effective donation strategy, here are a few prudent financial management tips to guide you along the way.
Pharmaceutical Executive August 1, 2012 Julian Upton	Brand Building -- Not! As a drug company promoting a drug free Olympiad, GSK wins our gold hands down for finally putting the industry's best face forward on the last frontier of advertising and the TV sets of Europe.
BusinessWeek November 29, 2004 Kerry Capell	"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome.
Chemistry World November 1, 2011 Sarah Houlton	A Shot in the Arm for Drugs for Neglected Diseases A new consortium of public and private sector partners has been launched by the World Intellectual Property Organization. Its aim is to share intellectual property that may help find drugs for malaria, tuberculosis and other neglected tropical diseases.
AFP eWire February 26, 2007	Family and Friends Best Way to Reach Donors A new survey by Cone Communications provides further evidence that the most effective way for charities to reach potential new donors and influence their giving decisions is through people they know.
Pharmaceutical Executive August 1, 2013 William Looney	One Company -- One Moment The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China -- ironically, the country touted as guarantor of our industry's future.
Pharmaceutical Executive April 1, 2011	Restoring Public Trust in Pharma Putting the focus on four steps to cement a new compliance culture.
Chemistry World October 31, 2008 Matt Wilkinson	GSK Snaps up Hepatitis Drug Developer In a bid to strengthen its efforts to develop new hepatitis therapies, GSK has agreed to buy Genelabs Technologies in a deal worth $57 million.
Chemistry World July 25, 2008 Sarah Houlton	Small is beautiful for GSK drug discovery New GlaxoSmithKline chief executive Andrew Witty is restructuring the firm's drug discovery, setting up small, highly focussed research teams that will have to bid for funding.
Pharmaceutical Executive April 1, 2014 Subramanian et al.	"Market-Based" Price Controls In India? Three strategic implications for pharma pricing strategies in India.
AskMen.com Michael Hirsch	How To: Volunteer For A Charity Many guys want to give back to society somehow. However, many of us can't afford to donate much money to worthy causes. That's why volunteering for a charity is a good alternative.
The Motley Fool November 29, 2006 Mary Dalrymple	A Few Cures for Charity Fatigue It may seem miserly to put your charitable donations on a budget, but sometimes, you just can't help it. Still, that doesn't mean you can't make a contribution to your favorite cause. You can help in other ways besides writing a check. Let's go through some ideas.
Chemistry World June 11, 2008 James Mitchell Crow	GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations.